Kailera

Quick facts

Phase 3 pipeline

• KAI-9531 · Oncology
  KAI-9531 is a small molecule that targets the PD-1 receptor.

Phase 1 pipeline

• KAI-7535

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kailera portfolio CI brief
• Kailera pipeline updates RSS